Mitoquinol Dosing & Safety
A Practitioner Guide
Mitoquinol mesylate is a ubiquinol derivative joined to a triphenylphosphonium (TPP) cation. The cation drives it into mitochondria in proportion to their membrane potential¹⁰,¹¹. That is why effective daily doses are measured in tens of milligrams. Untargeted CoQ10, by comparison, has been trialled at 1,200–2,400 mg/day¹².
Human trials have used 10–80 mg/day for up to 12 months, and the compound has been well tolerated in adults across cardiovascular, metabolic, renal, liver, neurological and exercise studies⁶,¹³. The consistent dose-related effect is gastrointestinal. The main gaps are pregnancy, lactation, childhood, use beyond 12 months and formal drug interaction studies.
Dosing in Practice
The practitioner range comes in 10 mg and 20 mg capsules. The ranges below set the product guidance beside the doses that have actually been tested.
| Clinical goal | Practitioner range1 | Doses and durations studied | Notes |
|---|---|---|---|
| Endothelial and cardiovascular function | 10–40 mg/day | 20 mg for 4–6 weeks in older adults, CKD, HFpEF and hypertension2,3,14,15; 40 mg for 16 weeks in type 2 diabetes7 | Monitor blood pressure if it is low or the patient takes vasodilators |
| Exercise performance and recovery | 10–20 mg/day | 20 mg for 10–28 days4,8,16 | Can be split between morning and pre-training1 |
| Fatigue and mitochondrial insufficiency | 5–20 mg/day | 20 vs 40 mg in MS fatigue; results unpublished17 | Lower doses may suit; consider pairing with magnesium, PQQ or NAD+ precursors1 |
| Longevity and maintenance | 5–10 mg/day | No dedicated long-term trials at these doses | Intended for continuous long-term use1 |
Titration
Start at 10 mg in patients prone to nausea, those with low blood pressure and those taking several medicines. Start other patients at 20 mg.
Step up gradually. One trial protocol used 20 mg for at least three days and moved to 40 mg only if it was tolerated⁵. Allowing two to four weeks between steps is a cautious clinical adaptation of that approach.
Treat 40 mg/day as the routine ceiling. At 80 mg/day, gastrointestinal effects caused most withdrawals in the longest trial⁶.
Once the goals are met, consider a 5–10 mg maintenance dose¹.
Important Nuances to Remember
Take it fasted: absorption is quick but has shown to be variable. A single 80 mg dose peaked at about 33 ng/mL in plasma roughly one hour after ingestion¹⁸, and levels differ between individuals, probably because gut absorption differs⁹. Food reduces bioavailability, which is why the guidance is to dose on an empty stomach⁵.
More is not proportionally more: with daily dosing at 40 or 80 mg, fasting plasma levels plateaued at around 5 ng/mL after about 10 days, with no significant difference between the two doses⁹. Moving from 40 to 80 mg therefore adds side effects without clearly adding exposure⁶.
Levels build over days: in one exercise study, a single 20 mg dose taken an hour beforehand changed no oxidative-damage marker. After 21 days at the same dose, nuclear and mitochondrial DNA damage fell in lymphocytes and muscle⁸. Response should be judged after weeks of dosing, not after a single dose.
Safety by Dose
Tolerability is good up to 40 mg/day for up to 12 months. The doses above that carry a clear gastrointestinal cost or have only been given briefly.
| Daily dose | Longest controlled exposure | Populations studied | Tolerability findings |
|---|---|---|---|
| 10–20 mg | 6 weeks; a 3-month trial is under way22 | Healthy older adults, CKD, HFpEF, hypertension, middle-aged men, trained and untrained exercisers, people recently exposed to SARS-CoV-22,3,14,15,23,24 | Well tolerated; no consistent adverse-event signal |
| 40 mg | 12 months6,13 | Parkinson's disease, dilated cardiomyopathy, hepatitis C, type 2 diabetes6,7,13,25 | Nausea in 31.2% vs 17.1% on placebo and vomiting in 14.6% vs 4.9%5. Withdrawals: 2 vs 1 on placebo6. In cardiomyopathy, fewer adverse events than placebo (26 vs 49)13 |
| 80 mg | 12 months6 | Parkinson's disease, hepatitis C; single doses in vascular studies6,25,26 | 13 withdrawals, mostly gastrointestinal6. 80 mg twice daily for 7 days was tolerated5 |
| 120–160 mg | Single doses or 3-day escalation only | Older adults, postmenopausal women, men with prediabetes2,27,28 | No adverse events reported after a single 160 mg dose in six healthy men28; no chronic data |
In animals, mice tolerated 230 mg/kg/day without toxicity or mutagenicity. That is roughly 1,100 mg/day for a 60 kg adult after body-surface scaling⁹. In chronic dog studies, the dose-limiting effects were gastrointestinal⁵.
Side Effects and How to Manage Them
Nausea and vomiting are the only consistent dose-related effects. Placebo groups also report nausea, so a symptom diary from baseline helps separate the two⁵.
Lower the dose first, then titrate up more slowly.
Taking the dose with food reduced gastrointestinal discomfort in one trial⁹, but it also lowers absorption⁵. This trade-off may be reasonable for patients who cannot tolerate fasted dosing.
Patients with gastrointestinal conditions that predispose to nausea were excluded from trials⁹. Start them at 10 mg.
Exercise recovery: in untrained men taking 20 mg/day for 14 days, peak eccentric torque recovered more slowly after muscle-damaging exercise, and creatine kinase rose more than with placebo²⁹. Other training studies found no blunting of endurance adaptations³⁰, and one found larger gains in peak power¹⁶. The signal is small and inconsistent. Even so, avoid starting mitoquinol immediately before a block of heavy, unaccustomed eccentric training. Our Exercise and Mitochondrial Health article covers this in more detail.
Tolerability is not the same as efficacy: well-tolerated 12-month trials in Parkinson's disease and dilated cardiomyopathy showed no benefit on their primary outcomes⁶,¹³. Set expectations by condition using the condition hubs.
When Caution is Warranted
Most of these cautions reflect missing evidence rather than observed harm.
| Situation | Why caution is advised | Evidence and caveats |
|---|---|---|
| Pregnancy and lactation | Safety not established1 | Excluded from trials; no human data5,9 |
| Under 18 years | Safety in children is unknown | Excluded from trials for that reason9 |
| Low blood pressure, nitrates or vasodilators | Improved nitric oxide signalling may add to blood pressure lowering1 | 20 mg/day lowered systolic pressure in hypertensive men15; additive effects not formally studied |
| Anticoagulant or antiplatelet therapy | Monitor for interaction risk1 | Reduced platelet activation in vitro31; no human bleeding or INR data |
| Gastrointestinal disease or nausea-prone patients | Nausea and vomiting are the dose-related effects5,6 | Start at 10 mg and titrate slowly |
| Hypersensitivity to CoQ10 or idebenone | Structurally related quinones | A trial exclusion criterion9 |
| Active chemotherapy or radiotherapy | Many of these treatments act partly through oxidative stress | No human data. Preclinical data are limited; one study found reduced breast cancer cell migration in vitro32. Coordinate with the oncology team |
Monitoring and Follow Up
| Measure | When to use it | Key limitation |
|---|---|---|
| Blood pressure, seated and standing | At baseline and after each dose increase in patients with low pressure or taking nitrates or vasodilators | Additive effects with these medicines have not been quantified |
| Gastrointestinal symptom diary | For the first 2–4 weeks and after each dose step | Placebo groups also report nausea5 |
| INR or bleeding history | In patients on anticoagulants | Precautionary only; no human interaction data1 |
| Oxidised LDL, MDA/TBARS, 8-OHdG | At baseline and at review, to show oxidative burden1 | Not tissue-specific; changes may not track symptoms |
| Validated fatigue and quality-of-life scales | At baseline and at 8–12 weeks | Subjective and open to expectation effects |
Reading the Literature: Why You Will See 80–160 mg
Several well-known studies use doses far above the practitioner range. They are research tools, not treatment regimens.
160 mg as a probe. In the vascular ageing trial, a single 160 mg dose taken an hour before testing showed how much mitochondrial oxidative stress was limiting endothelial function. The treatment dose in the same trial was 20 mg/day for six weeks, which improved flow-mediated dilation by 42%². A later study used the same probe in postmenopausal women²⁷.
80 mg single doses. One acute dose improved flow-mediated dilation in adults with low cardiorespiratory fitness but not in regular exercisers²⁶.
Short escalations. In an insulin clamp study, men with prediabetes took 40, 80 and 120 mg over three days before the trial day²⁸.
No chronic safety data exist at 120–160 mg/day. These protocols should not be used as maintenance doses.
Practical Questions
Can it be taken with food? Yes, if fasted dosing causes nausea. Expect somewhat lower absorption⁵,⁹.
Can the dose be split? For athletes, the practitioner guidance allows a morning dose and a pre-training dose¹. No study has compared the pharmacokinetics of split and single dosing.
Should it be combined with CoQ10? There is no evidence either way. Most trials excluded recent CoQ10 use, so the combination has not been tested⁵,⁹.
How long should a trial period last? Positive chronic trials ran for 4–16 weeks²,³,⁷. A review at 8–12 weeks is a sensible clinical default.
Is long-term use safe? Controlled data extend to 12 months at 40–80 mg/day⁶,¹³. The 5–10 mg maintenance range is intended for continuous use¹. Use beyond 12 months has not been studied in trials.
Should it be stopped before surgery? There are no data. Ask patients to disclose it to their surgical team, particularly if they take anticoagulants.
What Is Not Yet Known
Special populations. There are no human data in pregnancy, lactation or childhood.
Long-term use. No controlled trial has run beyond 12 months.
Drug interactions. No formal interaction studies have been published. The cautions for anticoagulants and vasodilators rest on mechanism and the product guidance¹,³¹.
Dose–response. Most trials tested a single dose. A 20 vs 40 mg comparison in MS fatigue has finished but is unpublished¹⁷.
Women. Several exercise and metabolic trials enrolled only men⁸,¹⁶,²⁸.
Tissue exposure. Plasma levels reflect mitochondrial exposure poorly. One study set out to measure muscle concentrations after an oral dose³³.
References
MitoQ Ltd. Practitioner Tech Sheet: MitoQ Practitioner Only Range (10 & 20 mg). 2026. For healthcare professionals.
Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056–1063. doi:10.1161/HYPERTENSIONAHA.117.10787
Kirkman DL, Stock JM, Shenouda N, et al. Effects of a mitochondrial-targeted ubiquinol on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study. Am J Physiol Renal Physiol. 2023;325(4):F448–F456. doi:10.1152/ajprenal.00067.2023
Broome SC, Braakhuis AJ, Mitchell CJ, Merry TL. Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists. J Int Soc Sports Nutr. 2021;18:58. doi:10.1186/s12970-021-00454-0
Study protocol: MitoQ for the treatment of metabolic dysfunction in asthma (NCT04026711). ClinicalTrials.gov. Protocol and SAP
Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord. 2010;25(11):1670–1674. doi:10.1002/mds.23148
Procter H, et al. [Mitoquinone and cardiac energetics in type 2 diabetes; BCS abstract — verify title]. Heart. 2025;111:A284–A288.
Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ, attenuates exercise-induced mitochondrial DNA damage. Redox Biol. 2020;36:101673. doi:10.1016/j.redox.2020.101673
Kelesidis T. Study protocol: An open label study in adults to test the efficacy of mitoquinone/mitoquinol mesylate to prevent severe viral illness (NCT05381454). ClinicalTrials.gov. Protocol and SAP
Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276(7):4588–4596. doi:10.1074/jbc.M009093200
Smith RAJ, Hartley RC, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33(6):341–352. doi:10.1016/j.tips.2012.03.010
Parkinson Study Group QE3 Investigators; Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543–552. doi:10.1001/jamaneurol.2014.131
Halliday BP, Owen R, Ragavan A, et al. A double-blind, randomized placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2026;27:74–77. doi:10.1093/ehjci/jeaf310
Bohmke N, et al. [HFpEF immune-cell bioenergetics abstract — verify title]. Physiology. 2024;39(S1):1473. doi:10.1152/physiol.2024.39.S1.1473
Masoumi-Ardakani Y, et al. Moderate endurance training and MitoQ improve cardiovascular function, oxidative stress, and inflammation in hypertensive individuals. Cell J. 2022;24:577–585. doi:10.22074/cellj.2022.8089
Broome SC, Pham T, Braakhuis AJ, et al. MitoQ supplementation augments acute exercise-induced increases in muscle PGC1α mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men. Redox Biol. 2022;53:102341. doi:10.1016/j.redox.2022.102341
MitoQ for fatigue in multiple sclerosis: a placebo-controlled trial (NCT04267926). ClinicalTrials.gov.
Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103. doi:10.1111/j.1749-6632.2010.05627.x
Doughan AK, Dikalov SI. Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal. 2007;9(11):1825–1836. doi:10.1089/ars.2007.1693
Reily C, Mitchell T, Chacko BK, Benavides GA, Murphy MP, Darley-Usmar VM. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. 2013;1(1):86–93. doi:10.1016/j.redox.2012.11.009
Rodriguez-Cuenca S, Cochemé HM, Logan A, et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med. 2010;48(1):161–172. doi:10.1016/j.freeradbiomed.2009.10.039
Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans (NCT04851288). ClinicalTrials.gov.
Pham T, MacRae CL, Broome SC, et al. MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men. Eur J Appl Physiol. 2020;120(7):1657–1669. doi:10.1007/s00421-020-04396-4
Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls. eBioMedicine. 2024;102:105042. doi:10.1016/j.ebiom.2024.105042
Gane EJ, Weilert F, Orr DW, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019–1026. doi:10.1111/j.1478-3231.2010.02250.x
Carlini NA, Harber MP, Fleenor BS. Acute effects of MitoQ on vascular endothelial function are influenced by cardiorespiratory fitness and baseline FMD in middle-aged and older adults. J Physiol. 2024. doi:10.1113/JP285636
Darvish S, et al. [Late-onset menopause, endothelial function and mitochondrial ROS — verify title]. Circ Res. 2025. doi:10.1161/CIRCRESAHA.124.325639
Fiorenza M, et al. Reducing the mitochondrial oxidative burden alleviates lipid-induced muscle insulin resistance in humans [verify full title]. Sci Adv. 2024;10:eadq4461.
Broome SC, Atiola RD, Braakhuis AJ, Mitchell CJ, Merry TL. Mitochondria-targeted antioxidant supplementation does not affect muscle soreness or recovery of maximal voluntary isometric contraction force following muscle-damaging exercise in untrained men: a randomized clinical trial. Appl Physiol Nutr Metab. 2022;47(7):762–774.
Shill DD, Southern WM, Willingham TB, Lansford KA, McCully KK, Jenkins NT. Mitochondria-specific antioxidant supplementation does not influence endurance exercise training-induced adaptations in circulating angiogenic cells, skeletal muscle oxidative capacity or maximal oxygen uptake. J Physiol. 2016;594(23):7005–7014. doi:10.1113/JP272491
Méndez D, Arauna D, Corvalán F, et al. Mitoquinone (MitoQ) inhibits platelet activation steps by reducing ROS levels. Int J Mol Sci. 2020;21(17):6192. doi:10.3390/ijms21176192
Capeloa T, Krzystyniak J, Rodriguez AC, et al. MitoQ inhibits human breast cancer cell migration, invasion and clonogenicity. Cancers. 2022;14(6):1516. doi:10.3390/cancers14061516
Concentration of MitoQ in human skeletal muscle (NCT04098510). ClinicalTrials.gov.

